ROCHESTER, N.Y., Sept. 30, 2020 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today is announcing that the Company's M400 Smart Glasses are being used by University Malaya Specialist Centre (USMC) in Malaysia and were part of a successful COVID-19 pandemic response study to limit the numbers medical personnel attending to the neurosurgical patients as a protective measure to conserve personal protective equipment. 

The study was centered around the Vuzix M400 Smart Glasses which were used during the daily ward round on neurosurgical patients in the Neurosurgery ICU at the University of Malaya Medical Centre (UMMC) in Malaysia using MEDCOM Vision software.  Prior to the use of smart glasses when the patient is in the isolation room, it was difficult to see the patient, it was difficult to monitor them, because of COVID-19 standard operating procedures.

The goal of the study was to determine if telemedicine delivered through smart glasses was feasible and effective in an alternative method of conducting ward rounds on neurocritical care patients during the pandemic.  As part of the study a random pair of Neurosurgery residents and specialists conducted consecutive virtual and physical ward rounds on neurocritical patients. A virtual ward round was first conducted remotely by a specialist who received real-time audiovisual information from a resident wearing smart glasses integrated with telemedicine.  Subsequently, a physical ward round was performed together by the resident and specialist on the same patient. The treatment management plans of both ward rounds were compared and the intra-rater reliability was measured.

During the study ten paired ward rounds were performed on 103 neurocritical care patients with excellent overall intra-rater reliability. Nine out of ten showed good to excellent internal consistency and one showed acceptable internal consistency. Qualitative analysis indicated wide user acceptance and high satisfaction rate with the alternative method.

The conclusion from the study confirmed that virtual ward rounds using telemedicine via Vuzix M400 Smart Glasses on neurosurgical patients in critical care was feasible, effective and widely accepted as an alternative to physical ward rounds during the COVID-19 pandemic.

"Vuzix M400 Smart Glasses are now operational in ICUs, operating rooms and medical clinics in many places all over the world.  We are excited to learn of this successful COVID-19 pandemic response study conducted by the University Malaya Specialist Centre, which provided independent 3^rd party validation of Vuzix Smart Glasses as a clinically proven, effective and widely accepted alternative to physical rounds during the COVID-19 pandemic," said Paul Travers, President and Chief Executive Officer at Vuzix. 

A copy of the recently published Journal Pre-proof of the medical paper can be accessed below:

Munusamy T, Karuppiah R, Faizal A Bahuri N, Sockalingam S, Cham CY, Waran V, Telemedicine via Smart Glasses in Critical Care of the Neurosurgical Patient – A COVID-19 Pandemic Preparedness and Response in Neurosurgery, World Neurosurgery (2020), doi: https://doi.org/10.1016/j.wneu.2020.09.076.

About Vuzix Corporation

Vuzix is a leading supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company's products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 166 patents and patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2019 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK, and Tokyo, Japan.  For more information, visit Vuzix website, Twitter and Facebook pages.

Forward-Looking Statements Disclaimer

Certain statements contained in this news release are "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward looking statements contained in this release relate to the Vuzix M400 Smart Glasses, our relationship and future business opportunities with University Malaya Specialist Centre, and among other things the Company's leadership in the Smart Glasses and AR display industry. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Media and Investor Relations Contact:

Ed McGregor, Director of Investor Relations, Vuzix Corporation ed_mcgregor@vuzix.com Tel: (585) 359-5985

Vuzix Corporation, 25 Hendrix Road, Suite A, West Henrietta, NY 14586 USA,
Investor Information – IR@vuzix.com www.vuzix.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/university-malaya-specialist-centre-umsc-neurosurgeons-turn-to-vuzix-smart-glasses-for-patient-care-in-the-icu-during-covid-19-pandemic-301142259.html

SOURCE Vuzix Corporation